Jahangir Ahdoot, MD
Pulmonary Disease · Irvine, CANPI 1568559102
Payments from drug & device makers
Across 326 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Philips North America LLC$526
- Inari Medical, Inc.$418
- Johnson & Johnson$377
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,352100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 115 | $2,030 |
| AstraZeneca | 44 | $1,388 |
| Boehringer Ingelheim | 32 | $1,023 |
| Philips North America LLC | 9 | $526 |
| Inari Medical, Inc. | 2 | $418 |
| Johnson & Johnson | 12 | $377 |
| Mylan Specialty L.p. | 11 | $308 |
| Electromed, Inc. | 11 | $218 |
| Regeneron Healthcare Solutions, Inc. | 5 | $191 |
| AbbVie | 16 | $173 |
| Insmed, Inc. | 11 | $173 |
| Harmony Biosciences LLC | 6 | $163 |
| Pfizer | 7 | $160 |
| NEW World Medical,inc. | 1 | $147 |
| Viatris Specialty LLC | 5 | $143 |
| Idorsia Pharmaceuticals US Inc | 2 | $134 |
| ANI Pharmaceuticals, Inc. | 4 | $123 |
| Vifor Pharma, Inc. | 3 | $85 |
| Sunovion Pharmaceuticals Inc. | 6 | $76 |
| Grifols USA, LLC | 2 | $75 |
| Novo Nordisk | 3 | $58 |
| Merck | 2 | $41 |
| Sumitomo Pharma America, Inc. | 1 | $40 |
| Circassia Inc. | 2 | $38 |
| Verona Pharma, Inc. | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 3 | $33 |
| CSL Behring | 1 | $33 |
| Pulmonx Corporation | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $14 |
| Itamar Medical Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$446
- AIRSUPRA$446
- FLOWTRIEVER CATHETER, S$418
- CT THROMBECTOMY SYSTEM KIT$418
- inCourage$336
- Kahook Dual Blade$147
- Clearpath$147
- Ahmed Glaucoma Valve$147
- Streamline$147
- Via360$147
- XARELTO$121
- AREXVY$121
- OFEV$119
- QUVIVIQ$113
How this compares
$8,380 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 38 | $491,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 315 | $382,123 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $173,051 |
| XareltoRivaroxaban | 126 | $141,646 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 67 | $82,244 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $73,065 |
| LinzessLinaclotide | 49 | $69,529 |
| EliquisApixaban | 59 | $66,303 |
| MyrbetriqMirabegron | 43 | $49,399 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $42,144 |
| JanuviaSitagliptin Phosphate | 25 | $32,536 |
| RestasisCyclosporine | 19 | $31,151 |
| Wixela InhubFluticasone Propion/Salmeterol | 77 | $25,513 |
| Spiriva HandihalerTiotropium Bromide | 27 | $21,948 |
| NamzaricMemantine Hcl/Donepezil Hcl | 15 | $21,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,030 | $608,060592 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat | $1,023 | $589,198118 claims |
| Johnson & JohnsonXarelto | $377 | $141,646126 claims |
| AbbVieLinzess, Restasis, Namzaric, Synthroid | $173 | $124,130100 claims |
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler | $1,388 | $76,84567 claims |
| PfizerEliquis | $160 | $66,30359 claims |
| MerckJanuvia | $41 | $32,53625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Irvine
- Aaron WeinbergIrvine$5.1M
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.